Literature DB >> 36273171

Patient-specific modeling of stroma-mediated chemoresistance of pancreatic cancer using a three-dimensional organoid-fibroblast co-culture system.

Sebastian Schuth1, Solange Le Blanc1,2,3,4, Teresa G Krieger5, Julia Jabs6,7, Christian Conrad8,9, Oliver Strobel10,11,12, Miriam Schenk1, Nathalia A Giese1, Markus W Büchler1, Roland Eils5,6.   

Abstract

BACKGROUND: Cancer-associated fibroblasts (CAFs) are considered to play a fundamental role in pancreatic ductal adenocarcinoma (PDAC) progression and chemoresistance. Patient-derived organoids have demonstrated great potential as tumor avatars for drug response prediction in PDAC, yet they disregard the influence of stromal components on chemosensitivity.
METHODS: We established direct three-dimensional (3D) co-cultures of primary PDAC organoids and patient-matched CAFs to investigate the effect of the fibroblastic compartment on sensitivity to gemcitabine, 5-fluorouracil and paclitaxel treatments using an image-based drug assay. Single-cell RNA sequencing was performed for three organoid/CAF pairs in mono- and co-culture to uncover transcriptional changes induced by tumor-stroma interaction.
RESULTS: Upon co-culture with CAFs, we observed increased proliferation and reduced chemotherapy-induced cell death of PDAC organoids. Single-cell RNA sequencing data evidenced induction of a pro-inflammatory phenotype in CAFs in co-cultures. Organoids showed increased expression of genes associated with epithelial-to-mesenchymal transition (EMT) in co-cultures and several potential receptor-ligand interactions related to EMT were identified, supporting a key role of CAF-driven induction of EMT in PDAC chemoresistance.
CONCLUSIONS: Our results demonstrate the potential of personalized PDAC co-cultures models not only for drug response profiling but also for unraveling the molecular mechanisms involved in the chemoresistance-supporting role of the tumor stroma.
© 2022. The Author(s).

Entities:  

Keywords:  Cancer-associated fibroblasts; Drug screening; Pancreatic cancer; Patient-derived organoids; Personalized oncology

Year:  2022        PMID: 36273171     DOI: 10.1186/s13046-022-02519-7

Source DB:  PubMed          Journal:  J Exp Clin Cancer Res        ISSN: 0392-9078


  41 in total

1.  Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma.

Authors:  Paolo P Provenzano; Carlos Cuevas; Amy E Chang; Vikas K Goel; Daniel D Von Hoff; Sunil R Hingorani
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

2.  TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.

Authors:  Rachel A Hesler; Jennifer J Huang; Mark D Starr; Victoria M Treboschi; Alyssa G Bernanke; Andrew B Nixon; Shannon J McCall; Rebekah R White; Gerard C Blobe
Journal:  Carcinogenesis       Date:  2016-11-01       Impact factor: 4.944

3.  Deoxycytidine Release from Pancreatic Stellate Cells Promotes Gemcitabine Resistance.

Authors:  Simona Dalin; Mark R Sullivan; Allison N Lau; Beatrice Grauman-Boss; Helen S Mueller; Emanuel Kreidl; Silvia Fenoglio; Alba Luengo; Jacqueline A Lees; Matthew G Vander Heiden; Douglas A Lauffenburger; Michael T Hemann
Journal:  Cancer Res       Date:  2019-09-04       Impact factor: 12.701

Review 4.  Pancreatic cancer.

Authors:  Jorg Kleeff; Murray Korc; Minoti Apte; Carlo La Vecchia; Colin D Johnson; Andrew V Biankin; Rachel E Neale; Margaret Tempero; David A Tuveson; Ralph H Hruban; John P Neoptolemos
Journal:  Nat Rev Dis Primers       Date:  2016-04-21       Impact factor: 52.329

Review 5.  Microenvironmental regulation of therapeutic response in cancer.

Authors:  Florian Klemm; Johanna A Joyce
Journal:  Trends Cell Biol       Date:  2014-12-22       Impact factor: 20.808

6.  Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines.

Authors:  Wu Huanwen; Liang Zhiyong; Shi Xiaohua; Ren Xinyu; Wang Kai; Liu Tonghua
Journal:  Mol Cancer       Date:  2009-12-21       Impact factor: 27.401

7.  Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer.

Authors:  Kenneth P Olive; Michael A Jacobetz; Christian J Davidson; Aarthi Gopinathan; Dominick McIntyre; Davina Honess; Basetti Madhu; Mae A Goldgraben; Meredith E Caldwell; David Allard; Kristopher K Frese; Gina Denicola; Christine Feig; Chelsea Combs; Stephen P Winter; Heather Ireland-Zecchini; Stefanie Reichelt; William J Howat; Alex Chang; Mousumi Dhara; Lifu Wang; Felix Rückert; Robert Grützmann; Christian Pilarsky; Kamel Izeradjene; Sunil R Hingorani; Pearl Huang; Susan E Davies; William Plunkett; Merrill Egorin; Ralph H Hruban; Nigel Whitebread; Karen McGovern; Julian Adams; Christine Iacobuzio-Donahue; John Griffiths; David A Tuveson
Journal:  Science       Date:  2009-05-21       Impact factor: 47.728

8.  Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells.

Authors:  K E Richards; A E Zeleniak; M L Fishel; J Wu; L E Littlepage; R Hill
Journal:  Oncogene       Date:  2016-09-26       Impact factor: 9.867

9.  Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors.

Authors:  Lucy Ireland; Almudena Santos; Muhammad S Ahmed; Carolyn Rainer; Sebastian R Nielsen; Valeria Quaranta; Ulrike Weyer-Czernilofsky; Danielle D Engle; Pedro A Perez-Mancera; Sarah E Coupland; Azzam Taktak; Thomas Bogenrieder; David A Tuveson; Fiona Campbell; Michael C Schmid; Ainhoa Mielgo
Journal:  Cancer Res       Date:  2016-10-14       Impact factor: 12.701

Review 10.  Diversity and Biology of Cancer-Associated Fibroblasts.

Authors:  Giulia Biffi; David A Tuveson
Journal:  Physiol Rev       Date:  2020-05-28       Impact factor: 37.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.